SCHEMBL27201535

SCHEMBL27201535

COc1ccc(Br)c(C(=O)C=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.50
MAPT P10636 2/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 2/20 0.47
ABCG2 Q9UNQ0 1/20 0.45
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
PKM P14618 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KDM4E B2RXH2 1/20 0.43
CTSL P07711 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
PDE4A P27815 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23457081 0.82 RAB9A (0.58) HPGDMAPTHTTNPSR1POLB
SCHEMBL31682610 0.82 RAB9A (0.58) HPGDMAPTHTTNPSR1POLB
SCHEMBL2905684 0.81 ABCG2 (0.67) MAPTHTTNPSR1POLBABCG2
SCHEMBL8426128 0.81 MAPT (0.49) HPGDMAPTHTTNPSR1POLB
SCHEMBL1652968 0.80 ALDH1A1 (0.59) HPGDMAPTHTTNPSR1POLB
SCHEMBL227238 0.80 SMN1; SMN2 (0.59) HPGDMAPTPOLBKMT2ACYP1A2
Water SCHEMBL9265170 0.79 MAPT (0.47) HPGDMAPTHTTNPSR1POLB
SCHEMBL30513967 0.79 TYK2 (0.51) MAPTHTTNPSR1POLBABCG2
SCHEMBL21668146 0.79 TYK2 (0.51) MAPTHTTNPSR1POLBABCG2
SCHEMBL7502111 0.79 HPGD (0.61) HPGDMAPTHTTNPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP HPGD 1760/4885MAPT 1360/4885HTT 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.